Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anlotinib and Trastuzumab Deruxtecan
- Development stage
- Phase 1
- Lead developer
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of anlotinib and trastuzumab deruxtecan is being investigated as a treatment option for various types of breast cancer, particularly HER2-positive and HER2-low breast cancer with brain metastases. This combination therapy leverages two distinct mechanisms: trastuzumab deruxtecan, an antibody-drug conjugate that targets HER2 receptors and releases a topoisomerase I inhibitor (deruxtecan/DXd) intracellularly, and anlotinib, a multi-target tyrosine kinase inhibitor. This dual approach aims to improve efficacy, especially in challenging settings like brain metastases.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)Tyrosine kinase
Beyond the preview
Go deeper on Anlotinib and Trastuzumab Deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anlotinib and Trastuzumab Deruxtecan.